{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pityriasis-versicolor/prescribing-information/oral-fluconazole/","result":{"pageContext":{"chapter":{"id":"ff895dc9-00a2-59b2-9e11-6529379ea8fd","slug":"oral-fluconazole","fullItemName":"Oral fluconazole","depth":2,"htmlHeader":"<!-- begin field 97d4657a-8336-4984-a3bd-27da9c14537d --><h2>Oral fluconazole</h2><!-- end field 97d4657a-8336-4984-a3bd-27da9c14537d -->","summary":"","htmlStringContent":"<!-- begin item 1599ce95-a656-4d8e-98db-12d69fddd8d6 --><!-- begin field 1377b2cc-869f-419f-848d-c93cfd373fbf --><!-- end field 1377b2cc-869f-419f-848d-c93cfd373fbf --><!-- end item 1599ce95-a656-4d8e-98db-12d69fddd8d6 -->","topic":{"id":"0fea6769-8496-527e-9900-49c0411410df","topicId":"c13665df-bfcd-4fcc-b476-7e462353856b","topicName":"Pityriasis versicolor","slug":"pityriasis-versicolor","lastRevised":"Last revised in April 2020","chapters":[{"id":"48061d3b-77de-5625-838f-3490efd16385","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a2b64334-2f3e-5682-a55c-d89347f8b48f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"ce5bd4c2-7fa7-58e8-83bd-614d945b9710","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"fd8be5be-8d54-5431-88b3-44c33e4401da","slug":"changes","fullItemName":"Changes"},{"id":"fc8f8e10-88b6-5879-a69c-18f87f3c8340","slug":"update","fullItemName":"Update"}]},{"id":"ef705ed5-a47f-528d-97cc-8d9af2963eb5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5fdd92bc-0340-527b-8689-d48f307ce6e3","slug":"goals","fullItemName":"Goals"},{"id":"ec48d89c-955c-5e3d-af73-6e587354a56d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ecafa7cb-70ed-551b-b6d1-ddcf4f6bed3d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fd61e511-1bf0-541e-8192-19970ba59e82","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"05312c95-9379-5709-872d-b3e10aebfcc0","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b5911b4a-ad4b-52c9-9bfe-a0978bdc63c5","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"08f0e975-952b-5ec7-a211-0f0a447d63b6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d63e7392-070c-56c9-890f-bc58ae7b5b3a","slug":"definition","fullItemName":"Definition"},{"id":"1fbe5c19-2ec5-50c3-b69f-a251b7bfbd1c","slug":"causes","fullItemName":"Causes"},{"id":"2e638f9d-1d65-5294-9020-379452470ca9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c223ff1b-62e0-5bc5-bb16-aee1037798a3","slug":"prognosis","fullItemName":"Prognosis"},{"id":"7e95bc3b-7443-5b1f-aa77-97a44859c0ee","slug":"complications","fullItemName":"Complications"}]},{"id":"5a3a3c2c-acb7-5f56-af38-2ddbcc543c8f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e5b4b862-ed72-5b87-88c3-cec73356d952","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c0059764-1025-5915-ae2c-8a71310be239","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9c584d50-0808-57d6-b5c7-cb1af47c1be2","fullItemName":"Management","slug":"management","subChapters":[{"id":"216757cf-4ca3-5974-b742-43171690f9df","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"05482fa5-1c4b-5f1b-8b8e-6137e274e4e5","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d7f1cba7-9069-572c-b52d-d9319951ed08","slug":"ketoconazole-2percent-shampoo","fullItemName":"Ketoconazole 2% shampoo"},{"id":"54569984-7427-54f7-b6cb-3522c344a0de","slug":"topical-imidazole-creams","fullItemName":"Topical imidazole creams"},{"id":"11062d95-1795-54d5-88e9-9c9d1464555e","slug":"selenium-sulphide-shampoo","fullItemName":"Selenium sulphide shampoo"},{"id":"ff895dc9-00a2-59b2-9e11-6529379ea8fd","slug":"oral-fluconazole","fullItemName":"Oral fluconazole"},{"id":"95b98848-e241-56a6-b83d-380420c23440","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"}]},{"id":"9d664332-8ca1-5c9d-a030-544c2adfea31","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5609556e-dbb4-56de-8035-bced2df7d533","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8e7f4e16-d4b6-59d4-919a-6eb3a9f60a94","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a652af6c-c591-5583-ba4e-0ce6cb952e3b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e7e76cf0-a6de-51cc-9a4b-89194241dc6d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d791c177-66f7-5aaa-ab09-a2079d32f854","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"12d54e36-6600-5446-83a4-05d3c235b7f0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f54e136f-01a7-5fed-a635-fa6f209d4e3f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"05482fa5-1c4b-5f1b-8b8e-6137e274e4e5","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"fee1a809-b10c-5c43-bf1a-47088b05f40e","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 8c1987ad-c9af-4a7c-876f-33021f6afda2 --><h3>What are the contraindications and cautions for oral fluconazole?</h3><!-- end field 8c1987ad-c9af-4a7c-876f-33021f6afda2 -->","summary":"","htmlStringContent":"<!-- begin item 86afc00e-ea6c-4c19-887d-173fcb011e7b --><!-- begin field 3bc70757-e220-4034-9e86-8e7f22b2185b --><ul><li>Avoid oral fluconazole in:<ul><li>People with acute porphyria.</li><li>Pregnant women.</li><li>People taking other drugs known to prolong the QT interval and which are metabolized via the cytochrome P450 (such as erythromycin).</li></ul></li><li>Use oral fluconazole with caution in:<ul><li>People at risk of QT prolongation — this includes people with cardiomyopathy, sinus bradycardia, arrhythmias, hypokalaemia, hypomagnesaemia, hypocalcaemia, or who are taking other medication known to cause QT prolongation (such as tricyclic antidepressants, antipsychotics, or antiarrhythmics).</li><li>Hepatic impairment or people taking concurrent hepatotoxic drugs — associated with serious hepatic toxicity including fatalities.</li><li>Renal impairment if estimated glomerular filtration rate (eGFR) is less than 50 ml per minute per 1.73m<sup>2</sup> — use the usual initial dose then halve the subsequent doses.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">BNF, 2020</a>]</p><!-- end field 3bc70757-e220-4034-9e86-8e7f22b2185b --><!-- end item 86afc00e-ea6c-4c19-887d-173fcb011e7b -->","subChapters":[]},{"id":"55d40671-f8ad-517b-a7b4-16142e504fd5","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 167b0312-3e34-47ed-81cd-2d7d17ac9f8c --><h3>What are the adverse effects of oral fluconazole?</h3><!-- end field 167b0312-3e34-47ed-81cd-2d7d17ac9f8c -->","summary":"","htmlStringContent":"<!-- begin item 4e206558-9924-4bfd-a4cb-6bc9794f8c6c --><!-- begin field 01a52b8b-e26c-4acc-9f60-78cf48a6b3f8 --><ul><li>Adverse effects reported commonly include:<ul><li>Headache, skin reactions, nausea, diarrhoea, abdominal pain, and flatulence.</li><li>Rare cases of agranulocytosis, neutropenia, QT prolongation, and serious hepatotoxicity have been reported.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">BNF, 2020</a>]</p><!-- end field 01a52b8b-e26c-4acc-9f60-78cf48a6b3f8 --><!-- end item 4e206558-9924-4bfd-a4cb-6bc9794f8c6c -->","subChapters":[]},{"id":"a164e2e1-773f-5bee-971e-63b1ffeba544","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 15c7d0e7-6f0e-4d76-b9fd-6e6834bab03f --><h3>What are the drug interactions of oral fluconazole?</h3><!-- end field 15c7d0e7-6f0e-4d76-b9fd-6e6834bab03f -->","summary":"","htmlStringContent":"<!-- begin item 86051a18-40e2-4c7a-aec7-7ffed7f12ce9 --><!-- begin field 7b6665b7-f336-49ed-ac0c-fb1dcd4a8298 --><ul><li>Fluconazole inhibits cytochrome P450 enzymes (CYP450), and may, therefore, increase the levels of many drugs that are metabolised by the CYP450.</li><li>Drug interactions include:<ul><li>Amiodarone — concomitant use may increase QT prolongation.</li><li>Antidiabetic drugs — frequent monitoring of blood glucose is recommended owing to reports of hypoglycaemia following concurrent use.</li><li>Antiretroviral drugs — fluconazole increases the levels of nevirapine, ritonavir, and tipranavir. Monitor for signs of increased adverse effects. Avoid doses of fluconazole greater than 200 mg daily.</li><li>Carbamazepine and phenytoin — plasma levels of these drugs are increased by fluconazole, and toxicity has been reported. Monitoring and dose adjustment are indicated.</li><li>Celecoxib — fluconazole increases plasma concentrations of celecoxib, manufacturer advises adjusting celecoxib dose.</li><li>Erythromycin — concomitant use is contraindicated as this may increase the risk of cardiotoxicity (prolonged QT interval, Torsades de Pointes).</li><li>Ergotamine and methysergide — avoid concurrent use, owing to the increased risk of ergotism.</li><li>Ciclosporin — fluconazole increases the concentration of ciclosporin, manufacturer advises caution.</li><li>Statins — fluconazole potentially increases the risk of rhabdomyolysis when given with atorvastatin, monitoring and adjustment of dose are recommended.</li><li>Theophylline — predicted to cause hypokalaemia (potentially increasing the risk of Torsade de Pointes) when given with fluconazole.</li><li>Tacrolimus — fluconazole is predicted to increase tacrolimus concentration – monitoring advised.</li><li>Warfarin — fluconazole inhibits warfarin metabolism by cytochrome P450 CYP2C9. Monitor the international normalized ratio (INR) closely and adjust dose.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">Baxter, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">ABPI 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pityriasis-versicolor/references/\">BNF, 2020</a>]</p><!-- end field 7b6665b7-f336-49ed-ac0c-fb1dcd4a8298 --><!-- end item 86051a18-40e2-4c7a-aec7-7ffed7f12ce9 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}